Views

CrossRef citations to date

Altmetric

Original Research

Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

Makito Miyake1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, JapanCorrespondence[email protected]

https://orcid.org/0000-0001-9503-7356 View further author information

Nobutaka Nishimura1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan;2 Department of Urology, Okanami General Hospital, Iga, Mie, Japan

https://orcid.org/0000-0003-2000-2612 View further author information

Takuto Shimizu1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan;3 Department of Urology, Saiseikai Chuwa Hospital, Nara, JapanView further author information

Mikiko Ohnishi4 Department of Urology, Matsusaka Chuo General Hospital, Matsusaka, Mie, JapanView further author information

Masaomi Kuwada4 Department of Urology, Matsusaka Chuo General Hospital, Matsusaka, Mie, JapanView further author information

Yoshitaka Itami5 Department of Urology, Nara Prefecture General Medical Center, Nara, JapanView further author information

Takeshi Inoue5 Department of Urology, Nara Prefecture General Medical Center, Nara, JapanView further author information

Kenta Ohnishi6 Department of Urology, Hoshigaoka Medical Center, Hirakata, Osaka, JapanView further author information

Yoshihiro Matsumoto6 Department of Urology, Hoshigaoka Medical Center, Hirakata, Osaka, JapanView further author information

Takanori Yoshida7 Department of Urology, Tane General Hospital, Osaka, JapanView further author information

Yoshihiro Tatsumi8 Department of Urology, JCHO Yamato Koriyama Hospital, Koriyama, Nara, JapanView further author information

Masatake Shinohara9 Department of Urology, Osaka Gyoumeikan Hospital, Osaka, JapanView further author information

Shunta Hori1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan

https://orcid.org/0000-0001-9514-9964 View further author information

Yosuke Morizawa1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan

https://orcid.org/0000-0001-7142-5901 View further author information

Daisuke Gotoh1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan

https://orcid.org/0000-0002-6056-3820 View further author information

Yasushi Nakai1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, JapanView further author information

Satoshi Anai1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, JapanView further author information

Kazumasa Torimoto1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan

https://orcid.org/0000-0003-2870-0466 View further author information

Katsuya Aoki1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, JapanView further author information

Tomomi Fujii10 Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, 634-8522, JapanView further author information

Nobumichi Tanaka1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, Japan;11 Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, 634-8522, Japan

https://orcid.org/0000-0001-9242-7877 View further author information

Kiyohide Fujimoto1 Department of Urology, Nara Medical University, Kashihara, Nara, 634-8522, JapanView further author information

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Satoru Taguchi, Taketo Kawai, Tohru Nakagawa & Haruki Kume. (2023) Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review. Japanese Journal of Clinical Oncology.
Crossref

Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Chihiro Ohmori, Norimi Takamatsu, Yoshitaka Itami, Akira Tachibana, Yoshihiro Matsumoto, Keisuke Kiba, Atsushi Tomioka, Hiroaki Yamamoto, Eijiro Okajima, Kuwata Masaomi, Keichi Sakamoto, Mitsuru Tomizawa, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka & Kiyohide Fujimoto. (2023) Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Japanese Journal of Clinical Oncology.
Crossref

Katsuhiro Ito, Yuki Kita & Takashi Kobayashi. (2022) Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. International Journal of Urology 30:9, pages 696-703.
Crossref

Hiroyuki Nishiyama, Yu Tanaka, Masahiro Hamada, Masahiko Ozaki, Toshihiko Minegishi, Yuichiro Ito, Shinichiroh Maekawa & Nobuyuki Yamamoto. (2023) Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance. BMC Cancer 23:1.
Crossref

Makito Miyake, Yuki Oda, Takuya Owari, Kota Iida, Sayuri Ohnishi, Tomomi Fujii, Nobutaka Nishimura, Tatsuki Miyamoto, Takuto Shimizu, Kenta Ohnishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer. Cancer Science 114:3, pages 1118-1130.
Crossref

Makito Miyake, Tatsuki Miyamoto, Takuto Shimizu, Sayuri Ohnishi, Tomomi Fujii, Nobutaka Nishimura, Yuki Oda, Yosuke Morizawa, Shunta Hori, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Tumor expression of Nectin-1–4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression. Pathology - Research and Practice 237, pages 154072.
Crossref

Takuto Shimizu, Makito Miyake, Nobutaka Nishimura, Kuniaki Inoue, Koyo Fujii, Yusuke Iemura, Kazuki Ichikawa, Chihiro Omori, Mitsuru Tomizawa, Fumisato Maesaka, Yuki Oda, Tatsuki Miyamoto, Keiichi Sakamoto, Keisuke Kiba, Masahiro Tanaka, Nobuo Oyama, Eijiro Okajima, Ken Fujimoto, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Kazumasa Torimoto, Nobumichi Tanaka & Kiyohide Fujimoto. (2022) Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Cancers 14:7, pages 1735.
Crossref

Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date